Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

67%

Ph not_applicable

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 2Efficacy & side effects

2(66.7%)

N/ANon-phased studies

1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Other(1)

Detailed Status

Completed2

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 22 (66.7%)

N/A1 (33.3%)

Trials by Status

completed267%

unknown133%

Recent Activity

0 active trials

Showing 3 of 3

completednot_applicable

Evaluation of Positioning Protocols on a Wheelchair in Hemiplegic Patients

NCT04268641

unknownphase_2

Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study

NCT02748707

completedphase_2

Study of of URC102 to Assess the Efficacy and Safety in Gout Patients

NCT04804111

Clinical Trials (3)

Showing 3 of 3 trials

NCT04268641Not Applicable

Evaluation of Positioning Protocols on a Wheelchair in Hemiplegic Patients

Completed

NCT02748707Phase 2

Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study

Unknown

NCT04804111Phase 2

Study of of URC102 to Assess the Efficacy and Safety in Gout Patients

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3